Vol. 46 | No. 1 | January-June 2018 Back

Open Access

Catheter Ablation Versus Non-Ablative Strategies for Ventricular Tachycardia in Patients with Ischemic Cardiomyopathy on Implantable Cardioverter-Defibrillator: A Systematic Review and Meta-Analysis

Carlo Andrew A. Buaya, Alex T. Junia, Keith Andrew Chan, Jeremy Anne Alcazar
Jun 2018 DOI 10.69944/pjc.f0d3c60ad3

Abstract

Background: Ventricular tachycardia (VT) is an abnormal rapid rhythm originating from the lower ventricles occurring commonly in patients with cardiomyopathic hearts. Three treatment options are available: implantable cardioverter defibrillator (ICD), antiarrhythmic medications or catheter ablation (or a combination of these options). This systematic review aimed to compare the efficacy of catheter ablation vs non-ablative techniques as treatment for VT in patients with ischemic cardiomyopathy.

Methods: This was a systematic review and meta-analysis of prospective studies that compared ablative vs non-ablative strategies in patients with ischemic heart disease and depressed left ventricular ejection fraction (LVEF). Outcomes of interest included the post-treatment rate of recurrent VT, appropriate ICD shocks and mortality.

Results: Pooled findings of five studies showed a non-significant difference in the odds of VT post-treatment between the ablation arm and the non-ablation arm (OR 0.61; 95% CI 0.34-1.10; p=0.10). Heterogeneity was high (I2=55%). Sensitivity analysis excluding one pilot study contributing to the heterogeneity revealed a statistically significant reduction in the odds of recurrent VT (OR 0.54; 95% CI 0.31-0.94; p=0.0.03). Pooled findings of four studies showed that ablation resulted in a lower rate of appropriate shocks post-treatment compared with the non-ablative group (OR 0.51; 95% CI 0.30-0.87; p=0.01. There was no significant difference in the mortality rate between catheter ablation and non-ablative strategies (OR 0.77; 95% CI 0.47-1.25; p=0.29).

Conclusion: Catheter ablation on top of ICD placement reduced the risk of post-treatment VT and appropriate shocks. However, these did not translate into a reduction in mortality.

KEYWORDS: catheter ablation, non-ablative strategies, implantable cardioverter defibrillator, ischemic cardiomyopathy.

References
  1. Tung R, Boyle NG, Shivkumar K. Catheter Ablation of Ventricular tachycardia. Circulation. 2010;122: e389-e391.
  2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannon DS, et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med, 346(12), 877–83.
  3. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. (2002). Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation, 105(5), 589–94.
  4. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999; 340: 1855-62.
  5. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295: 165- 71.
  6. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30: 1245-53.
  7. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004; 110: 112-6.
  8. Pacifico A, Johnson JW, Stanton MS, et al. Comparison of results in two implantable defibrillators. Am J Cardiol 1998; 82:875-80. Cassidy DM, Vassallo JA, Buxton AR,
  9. Doherty JU, Marchlinski FE, Josephson ME. The value of catheter mapping during sinus rhythm to localize site of origin of ventricular tachycardia. Circulation 1984; 69:1103-
  10. Kienzle MG, Miller J, Falcone RA, Harken A, Josephson ME. Intraoperative endocardial mapping during sinus rhythm: relationship to site of origin of ventricular tachycardia. Circulation 1984; 70:957-65.
  11. Morady, F., Harvey, M., Kalbfleisch, S. J., el-Atassi, R., Calkins, H., & Langberg, J. J. (1993). Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation, 87(2), 363–72.
  12. Calkins H, Epstein A, Packer D. Arria, A. M., Hummel, J., Gilligan, D. M., et al. (2000). Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol, 35(7), 1905–14.
  13. Divyang Patel, Vic Hasselblad. Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trial. J Interv Card Electrophysiol (2016) 45:111–117
  14. Szumowski L, Przybylski A, Maciag A, Derejko P, Bodalski R, Zakrzewska J, et al. (2009). Outcomes of a single centre registry of patients with ischaemic heart disease, qualified for an RF ablation of ventricular arrhythmia after ICD intervention. Kardiol Pol, 67(2), 123–7
  15. Karl-Heinz Kuck, Anselm Schaumann. Catheter ablation of stable ventricular tachycardia before defi brillator implantation in patients with coronary heart disease (VTACH): a multicenter randomized controlled trial. Lancet 2010; 375: 31–40.
  16. John L. Sapp, M.D., George A. Wells.Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N engl j med 375;2 nejm.org July 14, 2016.
  17. Vivek Y. Reddy, M.D., Matthew R. Reynolds, M.D Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy. N Engl J Med 2007; 357:2657-65.
  18. Karl-Heinz Kuck, MD; Roland Richard Tilz, MD. Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter–Defibrillator Interventions in Patients with Unstable Ventricular Arrhythmias and Coronary Artery Disease Results from the Multicenter Randomized Controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017;10: e004422. DOI: 10.1161/CIRCEP.116.004422
  19. Al-Khatib SA. Catheter Ablation for Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator (CALYPSO) Pilot Trial. J Cardiovasc Electrophysiol, Vol. pp. 1-7.
  20. Ghanbari H, Baser K, Yokokawa M, et al. Noninducibility in postinfarction ventricular tachycardia as an end point for ventricular tachycardia ablation and its effects on outcomes: a meta-analysis. Circ Arrhythm Electrophysiol 2014;7: 677–683.
  21. Mallidi J, Nadkarni GN, Berger RD, Calkins H, Nazarian S. Meta analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease. Heart Rhythm 2011;8: 503–510.
  22. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter– defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
  23. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004; 110:3760-5.
  24. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998;32: 1909–1915.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.